GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Shiller PE Ratio

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Shiller PE Ratio?

Xeris Biopharma Holdings does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xeris Biopharma Holdings Shiller PE Ratio Historical Data

The historical data trend for Xeris Biopharma Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Shiller PE Ratio Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial - - - - -

Xeris Biopharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xeris Biopharma Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Xeris Biopharma Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Shiller PE Ratio falls into.



Xeris Biopharma Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xeris Biopharma Holdings does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Xeris Biopharma Holdings  (NAS:XERS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xeris Biopharma Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings (Xeris Biopharma Holdings) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Executives
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015

Xeris Biopharma Holdings (Xeris Biopharma Holdings) Headlines

From GuruFocus

Xeris Biopharma Updates Its Outlook For 2022

By Business Wire Business Wire 01-05-2023